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Abstract A cross-over controlled administration study of
smoked cannabis was carried out on occasional and heavy
smokers. The participants smoked a joint (11 % Δ9-
tetrahydrocannabinol (THC)) or a matching placebo on two
different occasions. Whole blood (WB) and oral fluid (OF)
samples were collected before and up to 3.5 h after smoking
the joints. Pharmacokinetic analyses were obtained from these
data. Questionnaires assessing the subjective effects were
administered to the subjects during each session before and
after the smoking time period. THC, 11-hydroxy-THC (11-
OH-THC) and 11-nor-9-carboxy-THC (THCCOOH) were
analyzed in the blood by gas chromatography or liquid chro-
matography (LC)-tandem mass spectrometry (MS/MS). The
determination of THC, THCCOOH, cannabinol (CBN), and
Δ9-tetrahydrocannabinolic acid A (THC-A) was carried out
on OF only using LC-MS/MS. In line with the widely accept-
ed assumption that cannabis smoking results in a strong con-
tamination of the oral cavity, we found that THC, and also
THC-A, shows a sharp, high concentration peak just after
smoking, with a rapid decrease in these levels within 3 h.
No obvious differences were found between both groups
concerning THC median maximum concentrations measured
either in blood or in OF; these levels were equal to 1,338 and
1,041 μg/L in OF and to 82 and 94 μg/L inWB for occasional
and heavy smokers, respectively. The initial WB THCCOOH
concentration was much higher in regular smokers than in
occasional users. Compared with the occasional smokers, the
sensation of confusion felt by the regular smokers was much
less while the feeling of intoxication remained almost
unchanged.
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Introduction
Cannabis is the most widely used illegal drug in the world, and
Δ9-tetrahydrocannabinol (THC) is frequently detected in the
blood or oral fluid (OF) of impaired drivers arrested for erratic
driving or involved in road accidents [1, 2]. Accurate measure-
ments and proper interpretation of cannabinoid concentrations
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are therefore important in order to reconstruct the accident
scene, to evaluate the exact time of consumption, and to assess
the level of driving impairment. In this regard, the ability
(short-term) and fitness (long-term) to drive can be influenced
bymany parameters. One of them is the frequency of cannabis
use. Several studies suggest that heavy cannabis smokers are
less likely to feel the desired effects, as well as the adverse
symptoms, of acute cannabis smoking when compared with
light users [3]. One key issue is therefore to find identification
criteria that allow the distinction between these two groups of
consumers. In this respect, questionnaires and brief medical
examinations have a limited reliability. In general, it is pref-
erable to rely on objective data which complement the afore-
mentioned subjective observations. Chronic use can be
assessed by measuring cannabinoid concentrations in hair.
However, this matrix is not always available, or can be con-
taminated by cannabis smoke [4] or by contact with dirty
hands, thus making its interpretation quite challenging. Fur-
thermore, in comparative studies, discrepancies were found
between “positive” urine specimens and hair tested as “nega-
tive” [5, 6]. Thus, measurement of cannabinoids in biofluids
offers another strategy. To this end, Daldrup et al. [7] have
shown that, if the serum concentration of THCCOOH is lower
than 5 μg/L, the consumption is assumed to be occasional
while levels above 75 μg/L are associated with regular use.
This criterion could be applied in routine forensic examina-
tions provided serum samples are taken within a prescribed 8-
day period following the last cannabis use [6].
To demonstrate that the defendant or the car driver was
under the influence of cannabis during a relevant event, one
could demonstrate that blood levels of active cannabinoids at
the time of the event were compatible with the impairing
effects of cannabis. Another possibility is to show that the
time lapse between exposure to cannabis and the event was
less than a few hours. In this respect, OF and blood determi-
nation of cannabinoids can be helpful. Detection of THC in
OF has been associatedwith a strong contamination of the oral
cavity during smoking and to a recent cannabis use. On the
other hand, THC and its metabolites are only poorly excreted
from the blood and tissues into this matrix. In line with these
observations, analysis of OF revealed very high concentra-
tions of THC in OF just after cannabis smoking, while 11-
hydroxy-THC (11-OH-THC) was not detected and only trace
amounts of 11-nor-9-carboxy-THC (THCCOOH) were mea-
sured [8]. Studies that used intravenous administration of
THC have suggested that the transfer of THC from the blood
into OF is limited [9]. Since THCCOOH is not known to be
present in cannabis smoke, its detection in OF could only
result from active cannabis consumption.
Knowledge of the pharmacokinetic (PK) parameters of
cannabinoids in blood and saliva and of their mutual relation-
ship with drug effects should also help to assess the level of
impairment of the driver. On the other hand, the determination
of cannabinoids in urine can be used to demonstrate a canna-
bis exposure. In 2001, in a study on the detection of THC in
OF, Niedbala et al. [10] showed that, during the elimination
phase, THC levels in OF follow a similar decrease to those
observed in plasma after cannabis smoking. In 2004, Huestis
and Cone [11] obtained the same results using a controlled
administration of smoked cannabis. More recently, Laloup
et al. studied the correlation of THC concentrations in OF
and plasma [12]. Their results indicated a good correlation
between OF and plasma concentrations and were in concor-
dance with studies of Toennes et al. [13, 14]. However,
although THC is now commonly detected in OF, there is still
little information about other cannabinoids and the determi-
nation of their PK parameters in simultaneously, or near-
simultaneously, collected blood and OF specimens. Recently,
Lee et al. investigated the change in the OF/plasma cannabi-
noid ratios following controlled oral THC and smoked canna-
bis administration [15]. They suggest that a direct prediction
of plasma THC concentrations based on OF levels is not
appropriate. On the other hand, OF THCCOOH could esti-
mate plasma THCCOOH levels. Throughout the last decade,
several studies have been carried out to determine PK param-
eters of cannabinoids in blood, plasma, or serum [16–21] in
humans. Some other studies were performed with oral fluid
only [22] or in tandemwith serum [23] or plasma [11, 24] with
a limited number of ten participants in each study. Two, three,
and more compartment PK and kinetic models have been
applied with varying degrees of success to describe the can-
nabinoid time profiles [25]. Non-compartmental and PK/
pharmacodynamic approaches were also used. No general
consensus could be reached from any of these studies.
In this study, 23 heavy and 25 occasional cannabis users
smoked cannabis or a placebo joint during two separate ses-
sions. Whole blood (WB) and OF samples were collected
before and up to 3.5 h after smoking a joint or a placebo. PK
parameters of THC, 11-OH-THC, THCCOOH in WB, and of
THC, THCCOOH, cannabinol (CBN) and THC acid A
(THC-A) in OF were determined. The most salient features
that distinguish the kinetic profiles of the two consumer
groups are presented. The kinetic profiles are correlated to
two typical subjective effects of cannabis. We also outline the




The overall design of the study has been described in a
previous publication and its supportive information [26].
The study was expanded in order to include regular cannabis
smokers. The methods are briefly described below. Forty-
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eight healthy male volunteers between 18 and 30 years old, 23
heavy smokers, and 25 occasional smokers, who completed
the sessions successfully, are included in this study. All par-
ticipants underwent a structured interview conducted by a
medical staff (psychiatrist, clinician, and research technician).
The mean consumption of cannabis during the 3 months
preceding inclusion in the study was set to a minimum of
one joint per month and a maximum of one joint per week for
occasional smokers, while it was set to a minimum of ten
joints per month (i.e., 2.3 joints/week) and possibly less than
three joints per day for heavy smokers. These criteria were in
accordancewith those of Toennes et al. [21], who considered a
use higher than four times per week for heavy smokers and a
weekly use or less for the occasional cannabis users. Very
heavy cannabis smokers (up to several dozen joints per day)
were excluded because we considered them unable to refrain
from smoking during a full day and, above all, the day they
had to smoke the placebo. Volunteers who used any illegal
drug (cocaine, amphetamines, and opiates) other than canna-
bis were also excluded from the study. The urine test for THC
metabolites was required to be positive for subjects enrolled in
the group of regular smokers, but it could either be positive or
negative in occasional users. Subjects recruited for the study
participated in two independent cross-over experimental ses-
sions where they smoked either a joint of pure cannabis
(Bedrobinol, 11 % total THC (less than 0.5 % free THC
[27]), <1 % CBD, obtained from Bedrocan, Veendam, The
Netherlands) or a placebo (Santhica variety, no THC, < 0.1 %
CBD, provided by the French National Federation of Hemp
Growers, FNPC, Le Mans, France). Throughout the day, WB
and OF samples were collected. OF samples from occasional
smokers were collected a fewminutes before inhalation (t =0 h)
and afterwards at 0.65 and 2.75 h. OF samples from heavy
smokers were collected a fewminutes before inhalation (t =0 h)
and at 0.35, 0.65, 1.9, 2.75, and 3.5 h after inhalation. Speci-
mens were stored for a few hours at room temperature before
freezing and storage at −80 °C. WB samples were taken a few
minutes before inhalation (t =0 h) and at 0.2, 0.3, 0.4, 0.65, 1.9,
2.5, and 3.5 h after smoking the joint. Samples were immedi-
ately frozen and kept at −80 °C before analysis. For occasional
smokers, the last blood sample was omitted because exper-
imental sessions should not last more than 3 h after inhala-
tion. On six occasions during the experimental day, volun-
teers were also asked to fill out questionnaires on the
subjectively experienced effects of smoking a joint. Sub-
jective effects were assessed by asking participants to indi-
cate the intensity of their feeling on a 100-mm visual analog
scale (VAS) between 0 (no effect) and 100 (most intense
effect ever felt). The questionnaires were administered at
regular time intervals before and after smoking the cannabis
joint or its matching placebo.
This study was approved by the Cantonal Research Ethics
Committee (Vaud). The subjects gave written informed
consent and received financial compensation for their
participation.
Joint making and inhalation protocol
The cannabis plant material (0.7 g Bedrobinol or 0.8 g
Santhica variety) was chopped, and the pure ground-up buds
were added to a pre-rolled king-size joint with a roach. The
joints were of identical size and were visually indistinguish-
able. The enrolled subjects smoked the joints according to a
fixed paced procedure. Each inhalation cycle was composed
of four steps: getting ready and start signal, 3 s; inhalation, 2 s;
breath-holding, 5 s; exhalation and rest, 50 s. This sequence
was repeated until two thirds of the joint was consumed, up to
a line drawn 3 cm above the cardboard filter.
Estimation of the usual and actual smoked amount
of cannabis
So as to create the most realistic conditions for the subjects,
the volunteers were asked about their smoking habits and
ways of preparing joints. To estimate the amount of cannabis
used to prepare a self-made joint, a picture showing a joint and
increasing amounts of cannabis and tobacco, and a metric
scale, was shown to each participant. The self-reported
amount of cannabis used to make a joint was divided by the
number of participants sharing the same joint in a joint ses-
sion. The quantity actually smoked during this experiment
was determined by weighing the initial amount of cannabis
put into the joint and subtracting the residual amount found in
the left part and in the butt. In contrast to the usual habits of
smokers, the marijuana was not mixed with tobacco in order
to eliminate any nicotine effects.
Materials
THC, 11-OH-THC, THCCOOH, CBN, CBD, THC-A, and
internal standards THC-d3, 11-OH-THC-d3, THCCOOH-d9
were purchased from Cerilliant Corporation (Round Rock,
TX, USA). Oral fluid samples were collected with a
Quantisal™ (nal von minden GmbH, Regensburg, Germany)
device for heavy smokers and with Salivette® (Sarstedt AG,
Sevelen, Switzerland) for occasional users. When the study
began with the occasional consumers, the Quantisal™ collec-
tion device was still uncommon and the data relating to its use
were very incomplete. In recent years, published results have
demonstrated the superiority of the Quantisal™ over the
Salivette® sampling device [28], which is why it was selected
for the heavy smokers.
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Methods of analysis
Analyses of OF samples were performed according to a pre-
viously published procedure [8]. The collection devices were
weighed before and after OF sampling to determine the quan-
tity of OF collected. The concentrations were then expressed
in nanograms per milliliter of undiluted OF. OF was extracted
from the collection device by centrifugation (Salivette®) or by
squeezing the pad onto the walls of the plastic tube
(Quantisal™). Subsequently, methanol (1.5 mL) was added
to the saliva collector to wash off the residual cannabinoids.
The methanolic extracts were evaporated to dryness under N2
before adding the OF samples. The cannabinoids were then
extracted by a LLE with heptane/ethyl acetate (4:1, v/v ).
Chromatographic separation was achieved using a Dionex
UltiMate 3000 Rapid Separation LC system equipped with a
Kinetex C18 100A column (150×2.1 mm). Tandem mass
spectrometry (MS/MS) operated either in negative or positive
electrospray ionization mode was carried out on an ABSciex
API 5000™ triple quadrupole system. Limits of quantification
(LOQs) were 0.5 μg/L for THC, THC-A, CBN, and CBD and
0.08 μg/L for THCCOOH.
The blood samples of the occasional smokers were ana-
lyzed according to the procedure described by Thomas et al.
[29]. The cannabinoids were extracted from 500 μL ofWB by
a simple liquid–liquid extraction with hexane/ethyl acetate
(9:1, v/v ) and then derivatized with a mixture of trifluoroacetic
anhydride and hexafluoro-2-propanol as fluorinated agents.
Mass spectrometric detection of the analytes was performed in
the selected reaction-monitoring mode on a Varian 1200 L
MS/MS triple quadrupole instrument after negative-ion chem-
ical ionization. The LOQs of the method were 0.5 μg/L for
THC and 11-OH-THC and 2.5 μg/L for THCCOOH.
WB samples of the regular smokers were extracted
using the same procedure but analyzed by LC-MS/MS
without a derivatization step. The ion transitions, MS
parameters, and LC-MS/MS equipment were the same as
those described in the method used for the analysis of OF
samples. The LC-MS/MS method used for the analysis of
blood specimens was validated according to the recom-
mendations of the “Société Française des Sciences et
Techniques Pharmaceutiques”. The same quality control
(QC) specimens were used to cross-validate the gas
chromatography-MS/MS and the LC-MS/MS methods.
The two techniques gave the same results for the analysis
of the QCs; no significant difference was therefore ob-
served between both methods. The LC-MS/MS method
was linear for THC and 11-OH-THC from 0.5 to 20 μg/L
and for THCCOOH from 2.5 to 100 μg/L. The trueness
was determined with four QC (0.5, 1, 10, 20 μg/L for
THC and 11-OH-THC and 2.5, 10, 50, 100 μg/L for
THCCOOH) analyzed four times on the same day. The
results ranged between 86 and 115 %. The coefficients
of variation (CV) of interday and intermediate preci-
sions were lower than 15 % in all cases, except for
11-OH-THC at a concentration of 0.5 μg/L (25.8 %).
LOQ values were determined at the lower QC with
trueness higher than 85 % and CVs lower than 20 %.
LOQs were 0.5, 1, and 2.5 μg/L for THC, 11-OH-THC,
and THCCOOH, respectively.
Evaluation of the data
The concentration–time profiles were analyzed with a non-
compartmental PK approach, using Microsoft Excel 2007.
The maximum concentrations (Cmax) and their correspond-
ing times (Tmax) were obtained from the kinetics. The elim-
ination half-lives (T1/2) were calculated by log-linear regres-
sion of the concentration–time curves (from the result of
exponential regression of the data). The areas under the curves
(AUC) were estimated using the trapezoidal rule.
Results and discussion
Sociodemographic comparison of occasional and heavy
cannabis smokers
The sociodemographic characteristics are presented in Table 1.
The mean (SD) age was 23.9 (3.0) for occasional and 22.7
(2.4)years for heavy smokers. Paper-wrapped joints filled
with a half/half mixture of marijuana and tobacco was the
preferred way of consumption as reported in the self-
administered questionnaires. On average, the cannabis joints
were smoked from 3.5 to 77.9 occasions per month over the
past 3 months preceding the study, depending on whether they
were occasional or heavy smokers. When taking into account
the fact that joints are shared by several smokers, all partici-
pants included in the group of occasional users smoked one or
less joint per week. Weekly consumption in heavy cannabis
smokers was more evenly distributed between 2 and 13 joints
per week. One smoker admitted to consuming 25 joints per
week. Consequently, all the occasional users met the inclusion
criterion set for the frequency of use (between one joint per
month and one joint per week). The heavy smokers met the
minimum frequency of use considered as mandatory for in-
clusion in this group (between ten joints per month and two
joints per day). The subjects of both groups started to smoke
cannabis at a median age of 16.3 years. Their way of smoking
differed considerably. The heavy smokers reported inhaling
more deeply and preferring higher-dose joints than the occa-
sional subjects. Finally, it is interesting to note that almost all
the occasional smokers (22 out of 25) had a driving license,
whereas only 14 heavy cannabis users (out of 23) had one.
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Comparison of the usual and actual smoked amounts
of cannabis
The usual amount smoked varied considerably between indi-
viduals and frequency of use, with a median quantity of 0.3 g
for occasional smokers and 0.4 g for regular users. The actual
quantity of cannabis smoked was equal to 0.39 g for both
groups, with little variance for heavy smokers and a slightly
wider variance for occasional users. Taking into consideration
a mean concentration of 11 % THC in the Bedrobinol head
tops, the total quantity of THC used during each smoking
session was estimated at around 43 mg. By way of compari-
son, Mariani et al. [30] reported that an amount of 0.66 g is
used in making joints in the USA (generally uncut with
tobacco) while typical European joints contain 0.33–0.40 g
of plant material and 20–50 mg of THC. The typical THC
concentration was reported to be around 8 % for marijuana
and 10 % for hashish in France in 2010 (OFDT report, 2012);
corresponding results reported by the Swiss Society of Foren-
sic Toxicology were 11 % THC for marijuana and 16.8 % for
hashish for the second semester of 2012.
Kinetic profiles and pharmacokinetic parameters of THC,
11-OH-THC, and THCCOOH in whole blood
Figure 1 shows the individual time profiles of THC, 11-OH-
THC, and THCCOOH for heavy and occasional smokers.
Occasional and heavy smokers presented similar kinetics, ex-
cept for the THC, 11-OH-THC, and THCCOOH C0. As indi-
cated in Table 2, C0 were 2.1 and 0.3 μg/L for THC; 0.9 and
0 μg/L for 11-OH-THC; and 20 and 0 μg/L for THCCOOH for
heavy and occasional cannabis users, respectively. Heavy
smokers’ C0 were significantly higher (p <0.0001) than those
of occasional ones for each of the three cannabinoids.
Maximal concentration (Cmax), time to the maximal con-
centration (Tmax), elimination half-life (T1/2), and area under
Table 1 Sociodemographic characteristics and self-rated patterns of cannabis use in occasional and heavy smokers
Number Mean SD Median Maximum Minimum
Occasional smokers
Age 23.9 3.0 24 29 19
Ethnicity Caucasian (23), Asian (1), Eurafrican (1)
Driving license 22 (21 car, 1 motorbike)
Age at first cannabis use 16.3 2.9 16 23 9
Total years of lifetime cannabis use 7.6 3.2 7 15 4
Preferred forms of cannabis Marijuana (21), hashish (11), hashish oil (5), pollen (2)
Preferred methods of consumption Joint (25), water pipe (bong, bhang) (7), pipe (chillum,
sebsi) (10), cigar (blunt) (3), vaporizer (1)
Assessment of the usual size of a joint (grams) 0.4 0.3 0.3 1.0 0.1
Estimation of the [%] of cannabis in the cannabis/tobacco mix 47 18 50 70 20
Frequency of use (occasions/month, last 3 months) 3.5 2.3 3.5 10 1
Number of people with whom the joint is shared 3.3 1.0 3.5 5 2
Prefer light (L) or strong (S) cannabis 15 L, 9 S
Usually inhale deeply (yes/no) 7 Y, 20 N
Heavy smokers
Age 22.7 2.4 22 28 19
Ethnicity Caucasian (20), Asian (1), Eurafrican (2)
Driving license 14
Age at first cannabis use 16.3 2.3 16 20 12
Total years of lifetime cannabis use 6.3 2.9 6 13 2
Preferred forms of cannabis Marijuana (23), hashish (14), pollen (4)
Preferred methods of consumption Joint (23), water pipe (bong, bhang) (18), pipe
(chillum, sebsi) (17), cigar (blunt) (2), vaporizer (2)
Assessment of the usual size of a joint (grams) 0.4 0.1 0.4 1.0 0.1
Estimation of the [%] of cannabis in the cannabis/tobacco mix 52 15 50 70 15
Frequency of use (occasions/month, last 3 months) 77.9 51.7 62.5 250 20
Number of people with whom the joint is shared 2.5 0.9 2.5 4 0
Prefer light (L) or strong (S) cannabis 8 L, 15 S
Usually inhale deeply (yes/no) 19 Y, 4 N
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the curve (AUC2.5h and AUC3.5h) are presented in Table 2. T1/
2 and AUC2.5h were determined by blood samples collected
until 2.5 h after inhalation for both occasional and heavy
smokers in order to compare their individual PK parameters.
As blood samples were collected till 3.5 h after inhalation for
heavy smokers, AUC3.5h was also determined for this group.
THC, 11-OH-THC, and THCCOOH presented all a median
Cmax in blood that was higher for heavy users than for
occasional smokers: Median THC Cmax were 87 and
75 μg/L, median 11-OH-THC Cmax were 6.5 and
2.6 μg/L, and median THCCOOH Cmax were 41 and
13 μg/L for heavy and occasional smokers, respectively.
Unexpectedly, the difference in THC between the groups
was not significant. Before carrying out this study, we
suspected that experienced chronic users should have a
more efficient inhalation technique resulting in higher blood
concentrations than occasional smokers with less experi-
ence and a poor puffing method. Indeed, it is known that
the bioavailability of THC is variable and is influenced by
individual techniques and smoking experience [25, 31].
Since no obvious difference was found, we hypothesized
that the inhaled dose was less influenced by frequency and
previous experience/use since all smokers inhaled following
a fixed paced protocol and also because the experienced
cannabis smokers would be more able to titrate the effects
than the inexperienced ones. The observation that occasion-
al and heavy smokers consumed approximately the same
quantity of cannabis (0.4 g) is in line with this hypothesis.
Furthermore, the occasional subjects who smoked without
inhaling (i.e., those who “crapote”) were excluded. The fact
that the regular smokers felt the effects of confusion less
than the occasional users (see next paragraph) can be
explained by the development of tolerance, but also by a
better ability to titrate the effects, especially those perceived
as negative (confusion). On the other hand, the differences
between both groups were highly significant for 11-OH-
THC and THCCOOH (p <0.0001). For these two metabo-
lites, the differences could be explained by the frequency of
consumption and their long terminal half-life.
The three cannabinoids remained detectable in all blood
specimens until the end of the investigation day. THC, 11-OH-
THC, and THCCOOH levels were higher than the LOQ in all
the heavy smokers’ samples. Median THC concentrations
measured 2.5 h after smoking were 4.2 and 2.1 μg/L for the
heavy and occasional smokers, respectively, while median
THCCOOH concentrations at the same time were 26 and
7.1 μg/L. Thus, THCCOOH concentrations in the heavy
smokers were significantly higher than those of the occasional
cannabis users (p <0.0001).
As expected and presented in previous studies [11, 21, 23],
THC reached its highest concentration first, followed by 11-
OH-THC and by THCCOOH. Median THC Tmax were 0.20
and 0.23 h for the heavy and occasional groups, respectively,
while median 11-OH-THC Tmax were slightly delayed to
0.28 and 0.32 h and median THCCOOH Tmax even more
to 0.38 and 0.40 h. The differences between both groups for
the THC and THCCOOHwere not significant. It was margin-
ally significant for 11-OH-THC (p <0.05). THCCOOH Tmax
values were slightly different from those reported by Kauert
et al. [23] (mean of 0.25 h) and by Toennes et al. [21] (0.75 h
for heavy and 0.25 h for occasional smokers).
Median THC, 11-OH-THC, and THCCOOH AUC2.5h in
blood were higher for the heavy than for the occasional
smokers. THC AUC2.5h were 43 and 33 µg.h/L; 11-OH-
THC AUC2.5h were 10 and 4.2 μg.h/L, and THCCOOH
AUC2.5h were 79 and 23 μg.h/L for the heavy and occasional
smokers, respectively. THC AUC2.5h values were marginally
different between both groups (p <0.05). This could be ex-
plained by the fact that THC Cmax of the heavy smokers was
slightly higher than THC Cmax of the occasional smokers
(without being significantly different). On the other hand,
differences were highly significant for 11-OH-THC and
THCCOOH AUC2.5h (p <0.0001). These differences could
be explained as follows: AUC measured for the heavy
smokers included both past and recent inhalations, while those
Fig. 1 Time profiles of THC, 11-OH-THC, and THCCOOH in whole
blood.Upper subfigure a occasional smokers; bottom subfigure b heavy
smokers
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calculated for the occasional users reflected current inhalation
only. To better compare the AUC2.5h, those of regular
smokers were corrected by baseline subtraction. To this
end, a trapezoid area was calculated by multiplying the
investigated time-period (2.5 h) by the THCCOOH C0
level. This value was weighted by the terminal half-life
of THCCOOH [6]. The median corrected AUC2.5h for
heavy smokers was then 16.1 μg.h/L and not significantly
different from the THCCOOH AUC2.5h of occasional
smokers.
The THC T1/2 in blood was shorter than 11-OH-THC T1/2
which was also shorter than THCCOOH T1/2. Similar
observations were drawn by Kauert et al. in a study carried
out with recreational cannabis users [23]. In our study, median
THC T1/2 were 0.8 and 1.0 h for the occasional and heavy
smokers, respectively, while the corresponding value reported
by Kauert et al. was 1.4±0.1 h. Our calculated 11-OH-THC
T1/2 were 1.7 h for the heavy and 1.6 h for the occasional
smokers versus 1.9 h, as reported by Kauert. The same authors
indicated a THCCOOH half-life of 3.0 h while we found
respectively 3.3 and 3.9 h for the occasional and heavy can-
nabis users. These differences can be explained by the longer
observation time in the Kauert study (6 vs. 2.5 and 3.5 h in our
case). The investigation time period has a great influence on
Table 2 Pharmacokinetic pa-
rameters of THC, 11-OH-THC,
and THCCOOH in whole blood
for heavy and occasional smokers
C0 (μg/L) Cmax (μg/L) Tmax (h) AUC2.5h (μg.h/L) AUC3.5h (μg.h/L) T1/2 (h)
THC heavy
Median 2.1 87 0.2 43 45 1.0
Mean 2.4 95 0.2 47 50 1.0
SD 1.6 47 0.1 20 21 0.3
Min 0.8 37 0.1 19 20 0.5
Max 7.1 192 0.4 86 91 1.9
THC occasional
Median 0.3 75 0.2 33 – 0.8
Mean 0.3 76 0.2 31 – 0.9
SD 0.4 46 0.1 18 – 0.2
Min 0 8.2 0.2 4.1 – 0.7
Max 1.4 168 0.4 68 – 1.4
11-OH-THC heavy
Median 0.9 6.5 0.3 10 12 1.7
Mean 1.2 6.9 0.3 10 11 1.8
SD 0.8 3.4 0.1 4.1 5.0 0.5
Min 0.4 2.8 0.2 3.7 4.1 1.0
Max 3.0 16 0.4 17 20 3.1
11-OH-THC occasional
Median 0 2.6 0.3 4.2 – 1.6
Mean 0.1 3.4 0.4 4.7 – 2.7
SD 0.2 3.3 0.3 4.4 – 2.3
Min 0 0.6 0.2 0.7 – 1.0
Max 0.6 18 1.6 23 – 11
THCCOOH heavy
Median 20 41 0.4 79 99 3.9
Mean 22 45 0.4 90 113 3.8
SD 16 24 0.1 53 70 1.7
Min 2.5 17 0.2 28 35 1.7
Max 51 106 0.7 227 304 9.2
THCCOOH occasional
Median 0 13 0.4 23 – 3.33
Mean 1.3 15 0.4 27 – 4.45
SD 3.7 8.9 0.1 19 – 3.69
Min 0 2.0 0.2 3.7 – 1.59
Max 17 38 0.7 86 – 17.3
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the determination of the half-life; for instance, Wall et al. [32]
calculated a terminal half-life between 25 and 36 h for THC,
with a study lasting 72 h.
Pharmacokinetic parameters of THC, THC-A, CBN,
and THCCOOH for heavy and occasional cannabis smokers
in oral fluid
Median time profiles of THC, THC-A, CBN, and THCCOOH
are presented for the heavy smokers using a double y-axis plot
in Fig. 2. The right axis is used for THCCOOH concentrations
with a magnitude extending from 0 to 0.7 μg/L, and the other
data subset (THC, THC-A and CBN) used the left axis with a 1,
000 times higher range scaled from 0 to 700 μg/L. THC
concentrations reached very high values and significantly
exceeded those of THC-A and CBN which were quite similar.
THCCOOH concentrations were lower with a median peak
value below 400 ng/L. THCCOOH levels remained higher
than the LOQ value up to 2.5 h after inhalation. In all but one
sample of the heavy smokers, THC remained detectable in
oral fluid until 3.5 h after smoking. The median THC concen-
tration at the end of the investigation day was 22 μg/L. THC-
A was still detectable in 18 out of 23 samples with a median
concentration of 1.9 μg/L. As for THC, CBN remained de-
tectable to the end of the investigation period in all but one
sample, although its median concentration after 3.5 h was
much lower, 2.4 μg/L. Median THC concentrations measured
3.5 h after smoking were higher in OF than in blood (22 vs.
4.2 μg/L). This confirms that THC can be detected slightly
longer in oral fluid than in blood, as already reported by
Drummer [33] and Verstraete [34]. Consequently, oral fluid
could be an interesting matrix, offering a greater likelihood of
recent cannabis use detection. The presence of THC-A in OF
was likely to be due to its incomplete decarboxylation while
the presence of CBN was the consequence of THC oxidation
and pyrolysis occurring during the smoking of the joint [35,
36]. As THC-A remained detectable throughout the experiment,
its use as a marker of recent exposure is questionable. However,
since most THC/CBD-based medicines do not contain THC-A,
this molecule could be used as a marker to detect crude cannabis
use. The plant cannabinoid THC-A was also detected in serum
samples and was recently suggested as a possible marker to
differentiate an intake of illegal cannabis products from an
administration of therapeutic THC (dronabinol, Marinol™) [37].
Pharmacokinetic parameters, such as C0,Cmax,C t, Tmax,
AUC, and elimination T1/2 are listed in Table 3. The heavy
smokers presented C0 values significantly higher than those
measured for the occasional users for THC (p <0.0001), THC-
A (p <0.001), and CBN (p <0.001). The median THC C0 for
regular smokers was relatively high (9.7 μg/L). A null median
value was found for the initial THCCOOH concentration
which was determined prior to smoking. If THCCOOH could
be occasionally detected in heavy smokers, it remained unde-
tectable in occasional users.
Among all participants, THC Cmax ranged from 19 to
3,170 μg/L, with median Cmax values of the occasional
smokers reaching 1,320 μg/L and exceeding those of the
heavy users (636 μg/L). Similar differences were observed
with THC-A and CBN Cmax: THC-A Cmax were 130 and
59 μg/L and CBN Cmax were 125 and 81 μg/L for the
occasional and heavy smokers, respectively. THC-A peak
concentrations differed significantly between both groups
(p <0.01). The higher buccal contamination observed among
the occasional smokers could be explained by differences in
smoking and inhalation techniques. It is known that the bio-
availability of these cannabinoids can be influenced by many
Fig. 2 Time profiles of THC,
THC-A, CBN, and THCCOOH
in oral fluid for heavy smokers
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factors, e.g., how deep the smoke is inhaled in the lungs, the
number of puffs and puff volume, the strength of inhalation,
the size of smoked particles and the distribution between the
gas phase, and the particle phase and the residence time in the
mouth [9]. Heavy and occasional users smoked the same
quantity of cannabis (0.39 g). However, the cannabinoid con-
centrations in blood were slightly higher for the heavy than for
the occasional smokers, but not significantly different. We
suggest that, during inhalation, the occasional smokers kept
the cannabis smoke a little longer in their mouths than the
heavy users before its inhalation into the lungs. The mouths of
the occasional cannabis smokers could have been more con-
taminated, resulting in higher levels of THC, THC-A, and
CBN. Furthermore, extraction efficiency could have been
influenced by the type of saliva collector used for each group
of smokers, although both extraction methods were cross-
validated. Indeed, the interaction of the cotton roll of the
Salivette® or of the pad of the Quantisal™with the oral cavity
may have been different. A strong decrease in median con-
centrations of THC, THC-A, and CBN was observed for both
groups of smokers within 2.5 h. The magnitude of the de-
crease was significantly higher for heavy smokers with
p values (Mann–Whitney U test) lower than 0.05.
Almost no difference was observed for the time period
separating the first puff from the observed Cmax. THC,
THC-A, and CBN Cmax happened concurrently a short time
after inhalation of the cannabis joint (Tmax=0.3–0.4 h). A
similar observation has been already reported in several other
studies [11, 23, 38, 39]. For instance, theCmax determined by
Kauert et al. [23] for THC was already measured in the first
OF sample taken just 0.25 h after starting inhalation. The
concentrations were poorly related to the administered dose:
900±589 or 1,041±652 μg/L after smoking a joint containing
250 μg/kg body weight (BW) or 500 μg/kg BW, respectively.
Broad variations in the THC concentrations measured in OF
were observed between studies. For example, Milman et al.
[39] reported a median THC highest concentration of
2,629 μg/L at 0.25 h after smoking. Huestis and Cone [11]
indicated an OF THC Cmax of 5,800 μg/L 0.2 h after inha-
lation. Several parameters could explain these large variations
of THC Cmax in OF. First, the devices used for collecting OF
differ and may influence the THC levels recovered from the
saliva. The expectoration [39] provided undiluted OF. How-
ever, it presents some limitations, such as low specimen
volume, high viscosity, and decreased drug stability. Expec-
toration after stimulation with citric acid [11] enhances sample
volume, but also changes salivary composition, and could
affect cannabinoid concentrations in OF [40]. Collecting OF
with Quantisal or Intercept devices [23, 41] results in diluted
OF mixed with extracting buffer containing potential analyt-
ical interferents (detergent, coloring agent, preservative sub-
stances). Langel et al. [28] studied nine different collection
devices. Their conclusions were that the extraction buffer of
the collection devices may help to increase the recovery of
drugs and improve the stability of the samples. Secondly, the
type of joint, the concentration of THC in the cannabis plant
Table 3 Pharmacokinetic parameters of THC, THC-A, CBN, and
















Median 9.7 636 42 22 0.4 745 0.9
Mean 24 1047 70 60 0.5 1120 1.3
SD 59 967 77 103 0.6 1179 1.0
Min 0 19 1.1 0 0.2 25 0.3
Max 290 3170 232 140 3.5 4226 3.4
THC occasional
Median 0 1320 216 – 0.3 – –
Mean 0.6 1388 258 – 0.3 – –
SD 2.5 782 286 – 0.1 – –
Min 0 367 9 – 0.2 – –
Max 12 3110 1400 – 0.6 – –
THC-A heavy
Median 1.2 59 2.5 1.9 0.4 48 1.3
Mean 4.1 73 4.3 13 0.5 59 1.5
SD 7.3 59 6.1 50 0.7 41 1.1
Min 0 5.9 0 0 0 7.3 0.3
Max 32 240 29 8.6 3.5 162 4.4
THC-A occasional
Median 0 130 11 – 0.3 – –
Mean 0 334 37 – 0.3 – –
SD 0.1 610 84 – 0.1 – –
Min 0 4.8 0 – 0.2 – –
Max 0.5 2910 412 – 0.6 – –
CBN heavy
Median 0.5 81 4.0 2.4 0.4 83 1.0
Mean 1.2 107 5.4 3.8 0.4 101 1.1
SD 1.9 87 5.3 4.4 0.1 82 0.6
Min 0 6.0 0 0 0.2 5.5 0.4
Max 6.7 310 25 22 0.5 297 2.7
CBN occasional
Median 0 125 19 – 0.3 – –
Mean 0 192 29 – 0.3 – –
SD 0 198 23 – 0.1 – –
Min 0 17 0 – 0.2 – –
Max 0 756 79 – 0.6 – –
THCCOOH heavy
Median 0 0.3 0.1 0 0.6 0.6 1.3a
Mean 0.1 0.6 0.1 0.1 0.7 0.8 1.9a
SD 0.1 0.6 0.1 0.1 0.5 0.8 1.9a
Min 0 0.1 0 0 0.3 0.1 0.8a
Max 0.5 2.4 0.3 0.4 2.0 3.7 7.2a
a Parameters determined with ten values only
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material, and the quantity of THC inhaled are also influential.
In our study, volunteers smoked half a cannabis joint contain-
ing 11% THC, which corresponds to a median value of 43mg
of THC. Subjects enrolled in the study of Kauert et al. smoked
either 13.8–22.3 or 27.5–44.5 mg THC. Huestis and Cone
administered cannabis cigarettes with 3.55 % THC, which
corresponds to 33.8 mg THC. Milman et al. provided the
participants with joints containing 6.8 % THC. Thirdly, the
bioavailability of THC after cannabis smoking is variable and
influenced by individual techniques of inhalation and previous
history of use, as already mentioned [25, 31].
THCCOOHCmax ranged between 0.3 and 2.4 μg/L in the
heavy smokers. This metabolite was not detected in OF sam-
ples of the occasional smokers. Since THCCOOH is not found
in cannabis plants, neither in joints nor in cannabis smoke, its
presence in OF could result only from human metabolism.
THCOOH is very likely poorly excreted from the plasma into
the saliva as a free molecule [8]. Its concentration in OF is
related to that found in plasma. Our study has shown that
THCCOOH levels were significantly higher in the blood of
the heavy smokers than in the light users. Therefore, a lower
concentration was to be suspected and was subsequently
found to be below the detection value limit in the OF of the
occasional smokers compared with the heavy users. In con-
trast to THC, THC-A, and CBN peaks, THCCOOH highest
concentration level was time-delayed. The median (range) OF
THCCOOH Tmax occurred 0.6 (0.3–2.0 h) after inhalation.
These values correspond to those of Milman et al. [39]. They
determined cannabinoids in oral fluid and obtained a median
Tmax for THCCOOH of 1 h (range was between 0.25 and
2.0 h). The observed delay is in line with the assumption that
THCCOOH in OF originates from THC metabolism. Oral
fluid AUC and T1/2 for the occasional smokers could not be
determined because only two samples could be collected after
inhalation. Median AUC3.5h of THC was much higher in OF
than in blood (745 versus 45 μg/L h) because THC concen-
trations in OF widely exceeded those measured in blood. On
the other hand, THCCOOH was found in much lower con-
centrations in OF than in blood, explaining why the AUC3.5h
in OF was inferior to that in blood.
The samples of the ten volunteers who remained positive
until the end of the investigation day were used to calculate the
THCCOOH T1/2. The three final OF samples collected be-
tween 1.9 and 3.5 h were used. The median elimination T1/2
were respectively 0.9, 1.3, 1.0, and 1.3 h for THC, THC-A,
CBN, and THCCOOH. These values were not significantly
different from each other. Surprisingly, THC OF T1/2 was not
significantly different from THC blood T1/2. On the other
hand, the difference between THCCOOH T1/2 in OF and
blood was very significant (p <0.001). In a study lasting 4 h,
Huestis and Cone [11] estimated the OF terminal half-life of
THC to be 0.8 h, in line with the value obtained in our study
(0.9 h). In a longer study lasting 8 h, Toennes et al. [21] found
an identical T1/2 value of 1.6 h for occasional and chronic
users.
THC-A and CBN OF concentrations were correlated
to THC with a significant Spearman correlation coefficient
(ρ =0.71 and 0.88, p <0.001). Elimination half-lives of these
two cannabinoids were not significantly different from THC
T1/2, suggesting that the elimination of these three compounds
follows approximately the same course. The molar ratios of
THC-A/THC were determined during the day of experiment
for heavy and occasional smokers. In occasional smokers,
before smoking, THC was detected in only two OF samples
and THC-A in only one. Consequently, their molar ratios
could not be determined. The median THC-A/THC molar
ratios were 0.08, 0.07, and 0.05 at 0.35, 0.65, and 2.75 h after
inhalation, respectively. For heavy smokers, these median
ratios varied between 0.03 and 0.09 during the day of experi-
ment. For each group, the ratios were not significantly differ-
ent between each time points. Furthermore, we found no
significant differences between occasional and heavy
smokers.
Fig. 3 VAS scores for the feeling of intoxication and confusion and THC
time profile in whole blood after smoking a cannabis joint or a matching
placebo. Upper subfigure a occasional smokers; bottom subfigure b
heavy smokers
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Assessment of subjective effects with questionnaires
The median results for feelings of intoxication and confusion
are presented in Fig. 3a and b. One effect (intoxication) is
expected and can be considered as desired and rewarding,
while the second (confusion) is an unwanted side effect [42,
43]. The sensations felt by the occasional smokers are plotted
in the upper right side subfigure (a), while those experienced
by the heavy users are displayed in the lower subfigure (b).
The two subfigures are mirrored with inverted y-axes. The
placebo effects were very low and are only shown for the
sensation of intoxication. The feeling of intoxication after
placebo smoking was slightly more intense among the occa-
sional than the heavy smokers. The kinetic profiles of THC are
shown on the same graphs to correlate the blood concentra-
tions with the subjective effects. It is clear that cannabis
inhalation by the occasional smokers (Fig. 3a) induced a
strong feeling of intoxication and confusion immediately after
smoking, with a VAS score of 75 and 63, respectively. Then,
these effects decreased slowly but did not completely disap-
pear after 2.5 h (VAS score of 28 and 29). As to the heavy
smokers (Fig. 3b), the feeling of confusion (discontinuous
line) remained low (VAS score equal or lower than 4), where-
as the feeling of intoxication (straight line) reached significant
values immediately after inhalation (VAS 60). This effect
decreased rapidly and disappeared almost completely after
2.5 h (VAS score of 2). These results suggest that, in compar-
ison to occasional smokers, heavy smokers remain able to feel
the intoxication effects, but with less intensity, while the
negative symptoms (confusion) become strongly attenuated.
These differences between occasional and heavy smokers
could be explained by the specific habits of consumption
(frequency and dose) of each group. Heavy smokers are more
accustomed to the effects of cannabis than occasional users
and could therefore better manage the way they feel intoxi-
cated or confused. The weakened feeling of confusion among
heavy smokers reflects a greater tolerance to negative symp-
toms. These effects as felt by occasional smokers are
discussed in depth by Battistella et al. [26]. Similar effects
involving a tolerance mechanism have been found by others
and are presented in a recent paper of Theunissen et al. [44].
Limitations of the study
For each clinical trial, compromises and choices must be
made. In this broad cannabis administration study, two param-
eters have greatly influenced the time-schedule of the day of
experiment. First, we choose to keep the volunteers under
close supervision for several hours before administration of
the joint. The second parameter was the timing of the fMRI
sessions. Finally, the infrastructure of the clinical research
center, the ethical committee, as well as the volunteers’
availability were not compatible with a multi-day experiment.
The drawback was that a long investigation after inhalation
was not possible. Because two different OF collecting devices
were used, the comparison of the magnitude of cannabinoid
concentrations was difficult. However, our opinion is that the
concentration ratios and the variations in cannabinoid levels
can be profitably compared.
Conclusion
Pharmacokinetic analyses revealed that initial cannabinoid
concentrations in whole blood and oral fluid were different
between occasional and heavy smokers, especially in the case
of THCCOOH. However, occasional and heavy smokers pre-
sented a similar median THC maximal concentration in WB.
In OF, THC and to a lesser extent THC-Awere found in high
concentrations for both groups. The molar ratios of THC-A
over THC in OF remained the same during the day of exper-
iment and did not significantly differ between both groups of
consumers. The presence of THC-A in OF indicated that it is
only partially decarboxylated during the smoking of the joint.
Since THC-A is not known to be present in THC/CBD-based
medicines, it could be used as a marker of cannabis smoking.
Compared with occasional smokers, the intensity of the feel-
ing of confusion was much lower in heavy users while the
sensation of intoxication was only slightly lower.
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